ATLANTA–(BUSINESS WIRE)–Birios Therapeutics (Nasdaq: Vili), a development-stage biotechnology company focused on advancing novel combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, is today Chairman and CEO of Virios Therapeutics Greg Duncan announced that he will be attending and presenting at the Planet MicroCap Showcase. It will take place virtually December 6-8, 2022.
The company’s presentation will take place on Wednesday, December 7, 2022 at 10:00 am ET. The presentation will focus on a post hoc analysis of the recently completed Phase 2b FORTRESS (Fibromyalgia Outcomes Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus 1) study and an overview of its business and corporate strategy.
The presentation will be a webcast. To access the live presentation please use the following link: https://www.webcaster4.com/Webcast/Page/2937/47197
Archived recordings will be available for events and presentations on the investor section of the Virios Therapeutics website.
About Billios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing new antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”). Hypothesize that the immune response associated with the activation of tissue-resident herpes is a potential underlying cause that induces and/or perpetuates chronic diseases such as FM, irritable bowel disease, chronic fatigue syndrome, and other functional body syndromes. It has been. A reduction in symptoms with no apparent etiology. Our lead development candidate (“IMC-1”) is famciclovir, designed to synergistically inhibit herpes virus replication, with the ultimate goal of alleviating symptoms of virus-driven disease. and celecoxib are novel and proprietary fixed-dose combinations. IMC-1 has received Fast Track designation from the FDA.
The Company is developing a second antiviral therapy as a potential therapy for managing fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long-term COVID, also known as the acute sequelae of COVID-19. combination (valaciclovir and celecoxib). 19 (PASC). The Company has provided an unrestricted research grant to the Bateman Horne Center (“BHC”) to conduct this research. BHC is a non-profit, multidisciplinary Center of Excellence advancing the diagnosis and treatment of chronic fatigue disorders, FM, post-viral syndrome, and related complications.
For more information, please visit www.virios.com.
About Planet Microcap
Planet MicroCap is a global multimedia and publishing financial news investor portal with a special focus on covering the MicroCap market by providing news, insights, educational tools and expert commentary. The Planet Microcap Showcase will be held virtually, with over 50 companies, buy-side and sell-side analysts, wealth managers, institutional investors, family his offices, hedge fund managers, individual investors and more. Participating Sectors: Agriculture, Biopharma, Consumer, Energy, Financial Services, Healthcare, Industrial, Materials, Metals & Mining, Real Estate, Services, and Technology.
Follow Billios Therapeutics
Statements in this press release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The forward-looking statements contained in this press release are “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” ” seek, “may”, “could”, “plan”, “could”, “predict”, “plan”, “suggest”, “target”, “aim” , “should,” “will,” “will,” or the negation of or similar expressions to these words, although not all forward-looking statements contain those words. Risks associated with the completion, timing and results of current and future research or clinical studies related to Virios Therapeutics product candidates. These and other risks and uncertainties are discussed in more detail in the section entitled “Risk Facts”. rs” in its annual report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. does not undertake any obligation to update such information, except as required by applicable law.
View source version at businesswire.com: https://www.businesswire.com/news/home/20221129005166/en/